WuXi Biologics WKN: A2QJCN ISIN: KYG970081173 Forum: Aktien User: Summer.76

Hong Kong vaccine stocks plummeted by 20%-27% along with the periphery http://www.aastocks.com/tc/stocks/news/aafn-news/RUM.211004_140356/3

Danke für die Rückmeldung

Lässt sich leider irgendwie nicht gut kopieren, aber betrifft die Leerverkaufsquote (Übersetzer nötig): https://www.bastillepost.com/hongkong/article/9353425-%E5%8D%8A%E6%97%A5%E6%B2%BD%E7%A9%BA107-51%E5%84%84

Guten Morgen Summer.76! Ich bin auch noch am Start und bin auch weiterhin sehr dankbar über Deine Informationen hinsichtlich WuXi😊🙏🏼👍🏼!!!

Bin noch voll dabei 🤌

Alle mittlerweile abgesprungen hier 🤔? Überlege, den Chat dann zu schließen.

Phillip Huang Weijie: WuXi Biologics (02269) Kursziel von 142 Yuan, Stop-Loss-Preis von 116 Yuan https://www.quamnet.com/post/P-SxF1X8l9yXGSKm9BBI_ The Hang Seng Index fell more than 500 points at intraday, and the drop continued to expand by more than 2%. WuXi Biologics (02269) fell more than 7% and led the blue chip to drag the index nearly 70 points https://m.jrj.com.cn/madapter/hk/2021/10/04095833588615.shtml

HSI Deepens Slide to Over 600 pts; Financials, New Econ, Pharmas Decline; Alibaba Tests Trough  http://www.aastocks.com/en/stocks/news/aafn-con/RUM.211004_100821/recommend-news HSI opened low by 96 pts or 0.4% to post at 24,478 this morning, as it was weighed down by MEITUAN-W (03690 HK) ,  the property and financial sectors. The index then further widened its drop to 662 pts or 2.7%; last posted 23,913, on a turnover of $26.8 billion. The blue chip stocks broadly stumbled, with the pharmaceutical sectors facing the largest pressure. ...

Sihuan Pharmaceutical and WuXi Biologics develop new tumor treatment drugs https://m.hkej.com/landing/mobarticle2/id/2925935/%E5%9B%9B%E7%92%B0%E9%86%AB%E8%97%A5%E5%A4%A5%E8%97%A5%E6%98%8E%E7%94%9F%E7%89%A9%E7%A0%94%E7%99%BC%E8%85%AB%E7%98%A4%E6%B2%BB%E7%99%82%E6%96%B0%E8%97%A5 Sihuan Pharmaceutical ( 00460 ) announced that it has reached a R&D and production service cooperation with WuXi Biologics ( 02269 ) for an innovative tumor treatment drug KM501 bi-antibody ADC. It is currently in the pre-development stage of a new drug clinical trial application (IND). ...

Freitag bleibt HK wieder geschlossen. Noch in Bezug auf den Markt ab morgen: Die Auswirkungen der Aussetzung von Southbound Trading https://skypost.ulifestyle.com.hk/column/article/3069011/%E6%B8%AF%E8%82%A1%E9%80%9A%E6%9A%AB%E5%81%9C%E7%9A%84%E5%BD%B1%E9%9F%BF

Morgen ist die Börse in HK geschlossen.

Der Interim Report steht zum Download bereit: 2021 Interim Report Download https://www.wuxibiologics.com/wp-content/uploads/2021-Interim-Report.pdf

BioVaxys Bioproduction Partner WuXi Biologics Completes Synthesis Of Recombinant SARS-CoV-2 s-proteins for BVX-0320 and CoviDTH Programs https://finance.yahoo.com/news/biovaxys-bioproduction-partner-wuxi-biologics-070000538.html

http://www.aastocks.com/en/stocks/analysis/stock-aafn-con/02269/RUM.210913_110957/hk-stock-news HSI Craters Over 500 Pts on New Econ Shrs; Meituan/ WuXi Bio/ Galaxy/ Sands/ Wharf REIC Dive Over 5%

WuXi Biologics: Leading Global Biologics Outsourcing Company https://seekingalpha.com/article/4454473-wuxi-biologics-leading-global-biologics-outsourcing-company Summary • WuXi Biologics is the largest biologics outsourcing company in China, and among the top three industry players in the world. • The key risks for the stock are geopolitical tensions, policy risks in China, and weaker-than-expected profitability going forward. • WuXi Biologics trades at 140.5 times consensus forward FY 2021 P/E and and 97.1 times consensus forward FY 2022 P/E. ...